Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1 clinical study of ADXS-HER2 (ADXS31-164) for the treatment of patients with metastatic HER2 expressing solid tumors. On Thursday shares of Advaxis, Inc. (NASDAQ:ADXS) closed at $7.43.
OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) announced that a phase III study (AFFINITY) on custirsen has passed the interim futility analysis and is continuing as per the recommendation of the Independent Data Monitoring Committee. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) in last trading activity decreased -7.62% to close at $2.06. Company weekly performance is -9.65% while its quarterly performance stands at -6.36%. OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) is -85.54% away from its 52 week high.
Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, announced the pricing of its follow-on public offering of 2,550,000 shares of its common stock at a price to the public of $29.25 per share, for total gross proceeds of approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. On last trading day Otonomy, Inc. (NASDAQ:OTIC) decreased -14.31% to close at $29.34. Its volatility for the week is 8.73% while volatility for the month is 7.36%. Otonomy, Inc. (NASDAQ:OTIC) monthly performance is -19.59%.
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, on 16 January announced that the European Commission has granted marketing authorizations for AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets)1,2 with or without ribavirin (RBV) for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.1,2 The European Commission has also approved VIEKIRAX for use with RBV for the treatment of patients with genotype 4 (GT4) chronic HCV infection. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has 4.70% insider ownership while its institutional ownership stands at 82.10%. In last trading activity company’s stock closed at $46.00.
FibroGen (NASDAQ:FGEN) was downgraded by research analysts at Goldman Sachs from a “buy” rating to a “neutral” rating in a report released on Friday, TheFlyOnTheWall.com reports. They currently have a $32.00 target price on the stock. Goldman Sachs’ price objective suggests a potential downside of 5.60% from the stock’s previous close. On last trading day FibroGen, Inc. (NASDAQ:FGEN) decreased -6.32% to close at $29.81. Its volatility for the week is 7.81% while volatility for the month is 8.50%. FibroGen, Inc. (NASDAQ:FGEN) monthly performance is 8.56%.